Prelude TherapeuticsPRLD
NASDAQPharmaceuticals
No cached AI snapshot yet for PRLD.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
79 employees63.00M shares outstandinglisted 2020-09-25
Next earnings ~May 5, 2026
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
Latest News
Showing market-wide stock news
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Nifty holds above 23,250 level; European shares trade mostly in green
The Stock Market Is Sending a Rare Historical Warning. Warren Buffett Says Investors Should Make This 1 Move.
Related Stocksin Pharmaceuticals
Ready to see the live AI view on PRLD?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing PRLD side-by-side with live signals.